AKRO

Akero Therapeutics Inc

AKRO.US akerotx.com + Research + Basket
CIK 0001744659
Employees 74
Phone 650 487 6488
Fiscal year end December
IPO Jun 20, 2019
Address 601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Price N/A
USD · NASDAQ
52-week range
53.90
54.83
Market Cap
4.50B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
11.95
Div. Yield
N/A
% Institutions
112.47%
% Insiders
1.46%

1 Year

+75.6%

3 Year

+26.9%

10 Year

+198.3%
Description

Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.

Actions

Add an action for AKRO.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Andrew Cheng M.D., Ph.D. President, CEO & Director 1967
Dr. Jonathan M. Young J.D., Ph.D. Co-Founder, Executive VP, COO & Secretary 1970
Mr. William R. White J.D. Executive VP, CFO, Treasurer & Head of Corporate Development 1973
Mr. Scott A. Gangloff Chief Technical Officer 1974
Ms. Catriona Yale Executive VP & Chief Development Officer 1972
Dr. Timothy Rolph Ph.D. Co-Founder & Chief Scientific Officer 1954
Mr. Thomas Ross Senior VP & Head of Legal NA
Mr. John J. Schembri Senior VP & Head of Finance 1962
Mr. Patrick Lamy Senior Vice President of Commercial Strategy 1973

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Oct 10, 2025 Andrew Cheng N/A Sale 30.00K $53.98 $1.62M SEC
Oct 07, 2025 Timothy Rolph N/A Sale 12.50K $46.08 $576.00K SEC
Oct 01, 2025 Jonathan Young N/A Sale 12.50K $47.76 $597.00K SEC
Sep 11, 2025 Andrew Cheng N/A Sale 1.80K $43.02 $77.26K SEC
Sep 11, 2025 Catriona Yale N/A Sale 659.00 $43.02 $28.35K SEC
Sep 11, 2025 Jonathan Young N/A Sale 586.00 $43.02 $25.21K SEC
Sep 11, 2025 Timothy Rolph N/A Sale 553.00 $43.02 $23.79K SEC
Sep 11, 2025 William Richard White N/A Sale 659.00 $43.02 $28.35K SEC
Sep 10, 2025 Andrew Cheng N/A Sale 30.00K $43.25 $1.30M SEC
Sep 08, 2025 Timothy Rolph N/A Sale 12.50K $44.17 $552.13K SEC
Sep 02, 2025 Jonathan Young N/A Sale 12.50K $46.08 $576.00K SEC
Aug 12, 2025 Jonathan Young N/A Sale 12.50K $47.79 $597.38K SEC
Aug 11, 2025 Andrew Cheng N/A Sale 30.00K $48.59 $1.46M SEC
Aug 05, 2025 Timothy Rolph N/A Sale 12.50K $49.30 $616.25K SEC
Jul 16, 2025 Catriona Yale N/A Sale 10.00K $52.95 $529.50K SEC
Jul 10, 2025 Andrew Cheng N/A Sale 30.00K $51.16 $1.53M SEC
Jul 07, 2025 Timothy Rolph N/A Sale 12.50K $51.09 $638.63K SEC
Jul 01, 2025 Patrick Lamy N/A Sale 2.00K $52.88 $105.76K SEC
Jun 20, 2025 Patrick Lamy N/A Sale 875.00 $54.59 $47.77K SEC
Jun 18, 2025 Andrew Cheng N/A Sale 6.62K $54.84 $363.04K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 6.74M Jun 30, 2025 8.42% $0.18 -4.67%
BlackRock Inc 5.78M Jun 30, 2025 7.23% $0.01 -7.60%
General Atlantic Llc 5.73M Jun 30, 2025 7.17% $8.43 9.55%
RTW INVESTMENTS, LLC 5.48M Jun 30, 2025 6.85% $4.16 -26.17%
Vanguard Group Inc 4.53M Jun 30, 2025 5.66% $0.00 7.07%
T. Rowe Price Associates, Inc. 4.51M Jun 30, 2025 5.64% $0.03 -6.39%
venBio Select Advisor LLC 3.50M Jun 30, 2025 4.38% $3.27 0.00%
Wellington Management Company LLP 3.41M Jun 30, 2025 4.26% $0.03 -42.56%
Deep Track Capital, LP 3.04M Jun 30, 2025 3.80% $5.21 -5.22%
State Street Corp 2.75M Jun 30, 2025 3.43% $0.01 10.05%
Point72 Asset Management, L.P. 2.71M Jun 30, 2025 3.39% $0.28 433.29%
Woodline Partners LP 2.47M Jun 30, 2025 3.08% $0.70 413.24%
UBS Group AG 2.03M Jun 30, 2025 2.54% $0.02 -5.91%
Bellevue Group AG 1.99M Jun 30, 2025 2.48% $2.33 58.74%
Alkeon Capital Management, LLC 1.85M Jun 30, 2025 2.31% $0.16 19.34%
Geode Capital Management, LLC 1.72M Jun 30, 2025 2.15% $0.01 -1.53%
AllianceBernstein L.P. 1.54M Jun 30, 2025 1.92% $0.03 22.76%
Marshall Wace Asset Management Ltd 1.42M Jun 30, 2025 1.77% $0.09 -11.79%
Bank of America Corp 1.32M Jun 30, 2025 1.65% $0.01 406.70%
Logos Global Management LP 1.20M Jun 30, 2025 1.50% $7.08 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 2.41M 3.01% ▼ 2.05% Jul 31, 2025
2 iShares Russell 2000 ETF 1.68M 2.11% ▲ 0.00% Aug 31, 2025
3 US Small-Cap Growth II Equity Comp 1.63M 2.03% ▼ 10.19% Jun 30, 2025
4 Janus Henderson Global Life Sciences 1.44M 1.80% ▼ 7.55% Jun 30, 2025
5 Janus Henderson Global Life Sciences D 1.44M 1.80% ▼ 3.95% Jun 30, 2025
6 T. Rowe Price New Horizons 1.34M 1.68% ▼ 17.54% Jul 31, 2025
7 Vanguard Health Care Inv 1.26M 1.57% ▼ 65.59% Jun 30, 2025
8 Janus Global Life Science AUSD 1.18M 1.48% ▼ 5.97% Jun 30, 2025
9 SPDR® S&P Biotech ETF 1.14M 1.42% ▲ 0.22% Aug 31, 2025
10 T. Rowe Price Health Sciences 1.10M 1.38% ▼ 1.11% Jul 31, 2025

Financial Highlights

▼
Market Cap: $4.50B
EBITDA: $-329.99M
Book Value: $11.95
Earnings/Share: $-3.75
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -22.63%
ROE (TTM): -34.53%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $3.76B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 82.32M
Shares Float: 71.11M
% Insiders: 1.46%
% Institutions: 112.47%
Shares Short: 4.32M
Shares Short (Prior Month): 4.41M
Short Ratio: 2.33
Short % Float: 5.40%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-18.00K
Gross Profit
subtotal
$-18.00K
SG&A
adjust
$-37.93M
R&D
adjust
$-247.50M
Operating Income
subtotal
$-285.42M
Other / Non-Operating Items
adjust
$33.36M
Net Income
subtotal
$-252.06M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AKRO.US!